I know it is dangerous to get one’s “news” from Facebook and/or other social media platforms, but I was sufficiently intrigued by a post I came across to do some due diligence–to research its accuracy and check it out. The post in question noted that a drug named Leqembi is used to treat early symptoms of Alzheimers, that it is administered via infusion (often through the back of the hand), and that its use requires monitoring via regular MRIs.
The post ends with “why am I mentioning this? No reason,” a tongue in cheek disavowal of the obvious purpose of sharing the information. As most readers of this post will immediately recognize, the information–if accurate–is a likely explanation of the bruises on the back of Trump’s hand and the recent MRI he has been unable to explain. It is certainly consistent with the mental deterioration everyone outside the MAGA cult has observed.
The results of my (admittedly unscientific) research suggest that the post accurately describes the nature and purpose of Leqembi– generic name lecanemab. It is described as a drug that “targets amyloid-beta (a protein) in the brain,” and it was developed because medical experts believe that amyloid-beta plaques (otherwise known as clumps in the brain) play a key role in the development of Alzheimer’s disease.
Leqembi binds to these proteins and helps to clear them, slowing the progression of the disease. It isn’t a cure; rather, it’s
considered a “disease-modifying” therapy.
The Alzheimer’s Association describes it as follows:
Lecanemab (Leqembi®) is an antibody intravenous (IV) infusion therapy that targets and removes beta-amyloid from the brain. It has received traditional approval from the U.S. Food and Drug Administration (FDA) to treat early Alzheimer’s disease, including people living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease who have confirmation of elevated beta-amyloid in the brain. Leqembi lowers beta-amyloid in the brain and reduces cognitive and functional decline in people living with early Alzheimer’s.
Leqembi is administered by intravenous (IV) infusion every two weeks, and regular MRI scans are required.
Before starting treatment, there’s a baseline brain MRI, and during treatment, regular MRIs monitor for abnormal changes in the brain like swelling or bleeding, something that can occur when amyloid is being cleared. The manufacturer advises that additional MRIs be given before the 5th, 7th, and 14th infusions, and additional MRIs may be required if certain symptoms arise–symptoms that include confusion, visual changes, dizziness, edema, and gait problems.
There’s a reason doctors and psychiatrists consider it unethical to diagnose from a distance–absent an actual, in-person medical or psychological examination, there is no way to explain behaviors or symptoms with any certainty. In Trump’s case, his refusal to disclose accurate medical information (or for that matter, accurate financial information, i.e. tax returns) understandably gives rise to speculation that may or may not prove accurate. We should acknowledge that, but it is also obvious that the description of Leqembi–the reasons for prescribing it, the method of its administration, the need for MRIs, and the enumeration of the side effects–are consistent with what anyone looking at this walking (limping?) disaster of an egomaniac can see.
In a sane world, a situation where doctors are treating a president for a condition that clearly and negatively affects decision-making would immediately trigger invocation of the 25th Amendment. In our world, where a delusional president and would-be King surrounded by sycophants, grifters and assorted incompetents, a diagnosis of Alzheimers is just one more reason to dissemble, to cover up, to pretend that “Dear Leader” is hale and hearty.
The King isn’t naked, he’s wearing beautiful clothes.
This is unlikely to end well….
Comments